Beyond the Headlines, Columns-Drugs & Supplements, March 2006
March 14, 2006
iPLEDGE Program Started to Educate Women About Risk of Pregnancy With Accutane WASHINGTON, D.C. - The Food and Drug Administration recently implemented the iPLEDGE program to educate women about the risk of becoming pregnant while taking Accutane, an acne drug manufactured by Hoffman-La Roche. The FDA said the program was established on March 1 to reduce the risk of inadvertent pregnancy exposure by tightly linking negative pregnancy testing with dispensing of Accutane (isotretinoin). iPLEDGE is a computer-based risk management program designed to further the public health goal of eliminating fetal exposure to isotretinoin through a …
UPCOMING CONFERENCES
HarrisMartin’s Artificial Stone Silicosis Epidemic Litigation ConferenceJanuary 10, 2025 - Long Beach, CA
The Westin Long Beach
|
